Industry Reports
CPhI Report predicts record EBITDAs for CDMOs in 2022
Part one of the 2021 CPhI Annual Report predicts an increasingly bullish outlook for CDMOs in the next 2-3 years, with macro factors significantly driving up demand and prices for mergers and acquisitions. The full findings (featuring 10+ experts...
Industry Reports
Pharmapack Report 2021: US leads on drug device innovation but trails Europe on sustainability
Ahead of the first Pharmapack Europe to be held in nearly 18-months, Informa has released the results of its global drug delivery and packaging survey, with the USA once again leading ‘drug delivery and device innovation’, but lagging behind...
Industry Reports
Bachem reports excellent results for the first half-year 2021
Sales grow by 35.0% to CHF 239.1 million
EBITDA rises from CHF 53.0 million to CHF 75.5 million and a margin of 31.6%.
Operating income (EBIT) increases from CHF 40.3 million to CHF 61.9 million and a margin...
Industry Reports
Samsung Biologics Reports Strong SecondQuarter 2021 Financial Results
Samsung Biologics , a leading contract development and manufacturing organization, announced strong financial results for the secondquarter of fiscal 2021.
John Rim, CEO of Samsung Biologics, stated, “The second-quarter financial performance demonstrates our ability to maintain steady operations despite the...
Industry Reports
Samsung Biologics Issues Its First Annual Sustainability Report
Samsung Biologics, the world’s leading contract development and manufacturing organization (CDMO), published its first annual sustainability report, consolidating the company’s policies for an enhanced ESG management system and related plans. The report focuses on the company’s commitment to taking...
Industry Reports
Analysis of more than 160,000 COVID-19 patients shows obesity is the biggest indicator for severity of infection in under 40s
Virtual clinical development specialist, Phesi Inc., has today released findings from a significant analysis of COVID-19 patient profiles; based on data from 166,239 COVID-19 patients, from 523 cohorts/trial arms. The data includes patients from 56 countries, including the USA,...
Industry Reports
Real-World Effectiveness And Safety of Teduglutide in Adult Short Bowel Syndrome: A Meta-analysis
Randomized clinical trials have demonstrated that teduglutide, a glucagon-like peptide-2 (GLP-2) analog, improves intestinal absorption in patients with short bowel syndrome (SBS) with parenteral support (PS) dependence.1 Our objective was to assess real-world evidence of teduglutide effectiveness and safety...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read